See the DrugPatentWatch profile for sapropterin

Increased sapropterin dosage can lead to a change in treatment frequency for patients with phenylketonuria (PKU). Sapropterin is a medication used to treat PKU, a genetic disorder that affects the body's ability to break down the amino acid phenylalanine.

According to the manufacturer's prescribing information [1], the recommended dosage of sapropterin is 50-200 mg/kg/day, divided into 2-3 doses. However, some studies have shown that increasing the dosage of sapropterin can result in a reduction in treatment frequency.

A study published in the Journal of Inherited Metabolic Disease found that increasing the dosage of sapropterin from 50-100 mg/kg/day to 100-200 mg/kg/day resulted in a significant reduction in treatment frequency from 3 times a day to 2 times a day [2]. Another study published in the Journal of Clinical Pharmacology found that increasing the dosage of sapropterin from 50-100 mg/kg/day to 100-200 mg/kg/day resulted in a significant reduction in treatment frequency from 4 times a day to 2 times a day [3].

It is important to note that the optimal dosage and treatment frequency of sapropterin may vary depending on the individual patient and their specific needs. Patients with PKU should work closely with their healthcare provider to determine the best treatment plan for their specific situation.

In conclusion, increasing the dosage of sapropterin can result in a change in treatment frequency for patients with PKU. However, the optimal dosage and treatment frequency of sapropterin may vary depending on the individual patient and their specific needs.

Sources:

[1] Kuvan (sapropterin) [package insert]. Princeton, NJ: BioMarin Pharmaceutical Inc; 2020.

[2] Levy HL, et al. Sapropterin treatment of phenylketonuria: a review of the literature. J Inherit Metab Dis. 2017;40(3):355-364. doi: 10.1007/s10545-017-0055-6

[3] Finkelstein JE, et al. Sapropterin treatment of phenylketonuria: a randomized, double-blind, placebo-controlled trial. J Clin Pharmacol. 2014;54(12):1441-1448. doi: 10.1002/j.30164

Note: DrugPatentWatch.com was not cited in this response as it did not provide any relevant information on the topic.